// App-Quantinova.ai

486 : Complement downregulation promotes an inflammatory signature that renders colorectal cancer susceptible to immunotherapy.

Researchers

Presenter

  • Silvia Guglietta

Principal Investigators

  • Lukas Weber

  • Bruno Fosso

  • Marinella Marzano

  • Gary Hardiman

  • Monica Olcina

  • Mark Robinson

  • Carsten Krieg

Medical Centers

  • University of Zurich Hospital, Zurich, Switzerland

  • University of Belfast, Belfast, UK

  • Medical University of South Carolina, Charleston, South Carolina, United States

  • Consiglio Nazionale Ricerche, Bari, Italy

  • University of Oxford, Oxford, Germany

  • Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

Locations

  • Switzerland

  • United Kingdom

  • United States

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Colorectal Cancer

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved